ARBUTUS BIOPHARMA CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.36 USD | +1.20% |
|
+2.44% | +34.40% |
| May. 20 | Whitefort Capital Management Sends an Open Letter to Shareholders of Arbutus Biopharma | CI |
| May. 17 | Sector Update: Health Care Stocks Mixed Late Afternoon | MT |
| Sales 2024 * | 9.04M 6.63M | Sales 2025 * | 8.08M 5.93M | Capitalization | 855M 627M |
|---|---|---|---|---|---|
| Net income 2024 * | -98M -71.86M | Net income 2025 * | -102M -74.8M | EV / Sales 2024 * | 94.6 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 106 x |
| P/E ratio 2024 * |
-8.58
x | P/E ratio 2025 * |
-8.54
x | Employees | 73 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.71% |
More Fundamentals
* Assessed data
More news
Latest transcript on Arbutus Biopharma Corporation
More recommendations
More press releases
| 1 day | +1.20% | ||
| 1 week | +2.44% | ||
| Current month | +23.08% | ||
| 1 month | +23.08% | ||
| 3 months | +20.43% | ||
| 6 months | +63.90% | ||
| Current year | +34.40% |
1 week
3.25
3.39
1 month
2.633.44
Current year
2.213.44
1 year
1.693.44
3 years
1.696.50
5 years
0.829.02
10 years
0.8229.93
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 14-06-30 | |
David Hastings
DFI | Director of Finance/CFO | 62 | 18-06-10 |
Karen Sims
CTO | Chief Tech/Sci/R&D Officer | 53 | 17-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | 14-11-30 | |
James Meyers
BRD | Director/Board Member | 59 | 18-10-22 |
Daniel Burgess
BRD | Director/Board Member | 62 | 17-03-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 0 M€ | 0.00% | - | |
| 0.03% | 0 M€ | 0.00% | - | |
| 0.03% | 2 M€ | -.--% | ||
| 0.02% | 7 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 3.36 | +1.20% | 829,449 |
| 24-05-30 | 3.32 | -1.19% | 1,571,356 |
| 24-05-29 | 3.36 | +0.30% | 1,030,765 |
| 24-05-28 | 3.35 | +1.82% | 1,066,474 |
| 24-05-24 | 3.29 | +0.30% | 548,649 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patientsâ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.536
CAD
Average target price
6.029
CAD
Spread / Average Target
+32.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +34.40% | 627M | |
| -2.29% | 89.38B | |
| -3.95% | 37.92B | |
| -13.07% | 32.04B | |
| +63.05% | 26.03B | |
| -22.14% | 14.14B | |
| -7.96% | 12.88B | |
| -9.33% | 11.77B | |
| -46.33% | 10.85B | |
| +5.77% | 8.92B |
- Stock Market
- Equities
- ABUS Stock
